|
|
|
|
| LEADER |
01663nmm a2200397 u 4500 |
| 001 |
EB002003332 |
| 003 |
EBX01000000000000001166233 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
211020 ||| eng |
| 100 |
1 |
|
|a Elliott, Tim
|
| 245 |
0 |
0 |
|a Cancer immunotherapy
|h Elektronische Ressource
|c Tim Elliott
|
| 260 |
|
|
|a London
|b Henry Stewart Talks
|c 2021, 2021
|
| 300 |
|
|
|a 1 streaming video file (32 min.)
|b color, sound
|
| 505 |
0 |
|
|a Contents: Opportunities for immunotherapy -- Cytotoxic antibodies -- Monoclonal antibodies -- CAR T cells: engineered targeting -- Checkpoint blockade treatment -- Therapeutic vaccines -- Tumour specific neoantigens -- Current immunotherapy development landscape
|
| 653 |
|
|
|a Immunotherapy / trends
|
| 653 |
|
|
|a Cell Cycle Checkpoints
|
| 653 |
|
|
|a Neoplasms / therapy
|
| 653 |
|
|
|a Immunotherapy, Adoptive
|
| 653 |
|
|
|a Antineoplastic Agents, Immunological
|
| 653 |
|
|
|a T-Lymphocytes
|
| 653 |
|
|
|a Cytotoxicity, Immunologic
|
| 653 |
|
|
|a Neoplasms / immunology
|
| 653 |
|
|
|a Cancer Vaccines
|
| 653 |
|
|
|a Antibodies, Monoclonal
|
| 653 |
|
|
|a Cancer / Immunotherapy
|
| 653 |
|
|
|a Receptors, Chimeric Antigen
|
| 653 |
|
|
|a T cells
|
| 653 |
|
|
|a Antigens, Neoplasm
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b HST
|a Henry Stewart Talks
|
| 490 |
0 |
|
|a The immune system - key concepts and questions
|
| 500 |
|
|
|a Animated audio-visual presentation with synchronized narration. - Title from title frames. - Mode of access: World Wide Web
|
| 856 |
4 |
0 |
|u https://hstalks.com/bs/4562
|x Verlag
|z Streaming video file
|
| 856 |
4 |
2 |
|u https://hstalks.com/bs/p/1067
|3 Series
|
| 082 |
0 |
|
|a 570
|